Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOBILEMEN PrEP implementation trial in mobile men in sub-Saharan Africa
PACTR202409632006463Phase 3Recruiting
- Sponsor
- London School of Hygiene & Tropical Medicine
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in human immunodeficiency virus infection (HIV) comparing Oral PrEP arm with Long-acting injectable cabotegravir arm (2 arms). Primary endpoints: Short-term PrEP persistence, Long-term PrEP persistence and 2 more. Started Jul 2024; status: recruiting.
02
Drugs
cabotegraviremtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202409632006463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202409632006463.